Vancouver’s adMare BioInnovations is launching an accelerator to support growth of promising early-stage therapeutics ventures.
The Tx Accelerator will support the most promising ventures across Canada and help them achieve essential milestones for successful development and commercialization of therapeutics (Tx).
The 2020 adMare pilot accelerator program in Montreal, with support of the Ministry of Economy, Innovation and Energy (MEIE) and the Ville de Montréal generated significant results.
The first cohort of six companies – Cura Therapeutics, Modelis, Molecular Forecaster, Targa Biomedical, Trepso, and Valence Discovery – achieved important scientific and commercial milestones including technology validation, strengthening IP, increasing team size, company footprint and revenues, and successful fundraising.
adMare currently has 28 portfolio companies that have attracted $1.4 billion of risk capital, have a combined value of $3 billion, and have created over 1,000 jobs in Canada.
Based on the success of this program, adMare is launching the Tx Accelerator program nationally. To increase regional supports in Ontario adMare has partnered with MaRS Discovery District.
The Tx Accelerator provides integrated offerings that include: access to state of-the-art laboratory facilities and office space, scientific and regulatory guidance, expertise in business development and IP strategy, access to personalized training and team building, and financial support.
Therapeutic ventures are invited to submit their application by March 1st to be part of the first Tx Accelerator cohort.
adMare won the Milton Wong Award for Leadership at the 24th Annual Life Sciences BC Awards which recognize those who contribute to the vibrant life sciences ecosystem in B.C.